Document is current
Any future updates will be listed below
-
Authors
Therriault, Joseph https://orcid.org/0000-0002-7826-4781
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
Benedet, Andréa Lessa
Ashton, Nicholas J.
Arranz Martínez, Javier
Gonzalez-Escalante, Armand
Bellaver, Bruna
Alcolea, Daniel https://orcid.org/0000-0002-3819-3245
Vrillon, Agathe
Karim, Helmet
Mielke, Michelle M.
Hyung Hong, Chang
Roh, Hyun Woong
Contador, José https://orcid.org/0000-0002-9692-1570
Puig Pijoan, Albert https://orcid.org/0000-0002-9848-3711
Algeciras-Schimnich, Alicia
Vemuri, Prashanthi https://orcid.org/0000-0003-4286-0589
Graff-Radford, Jonathan
Lowe, Val J.
Karikari, Thomas K. https://orcid.org/0000-0003-1422-4358
Jonaitis, Erin
Brum, Wagner https://orcid.org/0000-0002-9777-0559
Tissot, Cécile https://orcid.org/0000-0003-2711-3833
Servaes, Stijn
Rahmouni, Nesrine
Macedo, Arthur C.
Stevenson, Jenna
Fernandez-Arias, Jaime
Wang, Yi-Ting https://orcid.org/0000-0002-9130-5461
Woo, Marcel S. https://orcid.org/0000-0002-1306-2708
Friese, Manuel A. https://orcid.org/0000-0001-6380-2420
Jia, Wan Lu
Dumurgier, Julien
Hourregue, Claire
Cognat, Emmanuel
Ferreira, Pamela Lukasewicz
Vitali, Paolo https://orcid.org/0000-0001-8953-1542
Johnson, Sterling https://orcid.org/0000-0002-8501-545X
Pascoal, Tharick A. https://orcid.org/0000-0001-9057-8014
Gauthier, Serge
Lleó, Alberto
Paquet, Claire
Petersen, Ronald C. https://orcid.org/0000-0002-8178-6601
Salmon, David
Mattsson-Carlgren, Niklas
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Galasko, Douglas
Son, Sang Joon
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Fortea, Juan https://orcid.org/0000-0002-1340-638X
Suárez-Calvet, Marc https://orcid.org/0000-0002-2993-569X
Jack, Clifford R. Jr https://orcid.org/0000-0001-7916-622X
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
- License Information
-
More Information
Article History
Received: 13 December 2023
Accepted: 25 September 2024
First Online: 12 November 2024
Competing interests
: J.T. has served as a consultant for the Neurotorium educational platform, outside of the scope of the submitted work. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program (outside submitted work). O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. R.C.P. has consulted for Roche, Genentech, Eli Lilly, Eisai and Nestle, all outside the scope of the current work. M.S.-C. has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L.; has given lectures in symposia sponsored by Roche Diagnostics, S.L.U and Roche Farma, S.A.; and was granted with a project funded by Roche Diagnostics International Ltd; payments were made to the institution (BBRC). A.P.P. has served at advisory boards for Schwabe Farma Iberica. D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). S. Johnson has served at scientific advisory boards or as a consultant for ALZpath, Prothena, Roche Diagnostics, and Enigma. M.M.M. has served as a consultant and at advisory boards for Biogen, Eisai, Lilly, Merck, Roche, and Siemens Healthineers. P.R.-N. has served at scientific advisory boards and/or as a consultant for Roche, Novo Nordisk, Eisai, and Cerveau radiopharmaceuticals. A.A.-S. has participated in advisory boards for Roche Diagnostics, Fujirebio Diagnostics and Siemens Healthineers. The remaining authors declare no competing interests.
